Table 1.
Association between CD155 expression and the clinicopathological features of patients with cervical cancer.
| Characteristics | CD155 expression | P | ||
|---|---|---|---|---|
| Patient | Low | High | ||
| N = 65 | N = 30 | N = 35 | ||
| Age | ||||
| < 45 | 25 | 11 | 14 | 0.7997 |
| ≥45 | 40 | 16 | 24 | |
| Clinicalstage | ||||
| Stage I | 46 | 21 | 25 | 0.4082 |
| Stage II/III | 19 | 6 | 13 | |
| Differentiation | ||||
| Low/moderat | 53 | 19 | 34 | 0.0608 |
| High | 12 | 8 | 4 | |
| Tumor size | ||||
| <4cm | 40 | 17 | 23 | >0.9999 |
| ≥4cm | 25 | 10 | 15 | |
| LNM | ||||
| Negative | 44 | 20 | 24 | 0.4259 |
| Positive | 21 | 7 | 14 | |
| DSI | ||||
| <1/2 | 15 | 10 | 5 | 0.0363* |
| ≥1/2 | 50 | 17 | 33 |
SCC, squamous cell carcinoma; LNM, lymph node metastasis; LVSI, lymph vascular space involvement; DSI, deep stromal invasion.
*Statistically significantly value.